|
FDA rules aim to speed drug tests and trim costs |
|
|
|
|
Friday, 13 January 2006 |
|
The Food and Drug Administration yesterday issued new guidelines that make it easier for scientists working in universities and small companies to test promising therapies in humans without matching the hefty spending of large drug companies. |
|
Read more...
|
|
|
ACNP Task Force Ties to Pharma |
|
|
|
|
Thursday, 12 January 2006 |
|
Authors of the American College of Neuropsychopharmacology Task Force on SSRIs and Suicidal Behavior in Youth: their known ties to the pharmaceutical industry |
|
Read more...
|
|
|
Chief Respiratory Care Mass General Hospital-Harvard-Rejects ARDS Recommendation |
|
|
|
|
Tuesday, 10 January 2006 |
|
A critical editorial by Dr. Robert M Kacmarek, Head of Respiratory Care Services at Massachusetts General Hospital and professor at Harvard University—the coordinating center for the ARDS Network, calls into question the validity of the ARDS Network recommendation of treating all patients with ALI-ARDS with a fixed, low air ventilation setting (6 mL/ kg). |
|
Read more...
|
|
|
Unhealthy Medicine-Wash Post_Drug Profits Infect Medical Studies--LA Times |
|
|
|
|
Tuesday, 10 January 2006 |
”SO WHY,” he asks, “DID American doctors prescribe $7 billion worth of Vioxx after Merck and the Food and Drug Administration knew all this?”
|
|
Read more...
|
|
|
FDA: NIMH SSRI Study Flawed--No Comparative Untreated Group |
|
|
|
|
Tuesday, 10 January 2006 |
Even Dr. Robet Temple, FDA Medical Policy Director of the Center for Drug Evaluation & Research dismisses the claimed finidings of a flawed, but highly trumpeted recent SSRI study published in the American Journal of Psychiatry. The study was sponsored by the National Institute of Mental Health.
|
|
Read more...
|
|
|
|
<< Start < Prev 61 62 63 64 65 66 67 68 69 70 Next > End >>
|
| Results 568 - 576 of 652 |
